Revisiting rates of reactivation tuberculosis: A population-based approach

American Journal of Respiratory and Critical Care Medicine

Volumn 182, Issue 3, 2010, Pages 420-425

  Horsburgh Jr , C Robert ^a,b   O'Donnell, Max ^b   Chamblee, Sandra ^c   Moreland, Janet L ^d   Johnson, Johnny ^c   Marsh, Bryan J ^e   Narita, Masahiro ^f   Johnson, Linda Scoles ^g   Von Reyn, C Fordham ^e  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Glades Health Initiative Inc   (United States)

^d C L Brumback Health Center   (United States)

^e DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g SCIENCE APPLICATIONS INTERNATIONAL CORPORATION   (United States)

Author keywords

HIV infections; Mycobacterium tuberculosis; Southeastern United States; Tuberculin test; Tuberculosis

Indexed keywords

ADULT; ARTICLE; CLUSTER ANALYSIS; DISEASE SURVEILLANCE; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; POPULATION RESEARCH; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; TUBERCULIN TEST; UNITED STATES; AGE; AIDS RELATED COMPLEX; DEMOGRAPHY; MIDDLE AGED; RECURRENT DISEASE; RISK FACTOR; RURAL POPULATION; TUBERCULOSIS;

AGE FACTORS; AIDS-RELATED OPPORTUNISTIC INFECTIONS; CLUSTER ANALYSIS; FEMALE; FLORIDA; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RECURRENCE; RESIDENCE CHARACTERISTICS; RISK FACTORS; RURAL POPULATION; TUBERCULIN TEST; TUBERCULOSIS;

EID: 77956623765     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200909-1355OC     Document Type: Article

References (43)

1. Pratt R, Robison V, Navin T. Trends in Tuberculosis - United States, 2006. MMWR Morb Mortal Wkly Rep 2007;56:245-250.
2. Horsburgh CR, MooreM, Castro KG. Epidemiology of tuberculosis in the United States. In: Rom WN, Garay SM, editors. Tuberculosis, 2nd ed. Philadelphia PA: Lippincott Williams and Wilkins; 2004. pp. 31-45.
3. Horsburgh CR. Prioritizing treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:260-267.
4. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Disease Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005;172:1169-1227.
5. Small PM, Hopewell PC, Singh SP, Paz A, Parsonnet J, Ruston DC, Schecter GF, Daley CL, Schoolnik GK. The epidemiology of tuberculosis in San Francisco. A population-based study using conventional and molecular methods. N Engl J Med 1994;330:1703-1709.
6. Geng E, Kreiswirth B, Driver C, Li J, Burzynski J, DellaLatta P, LaPaz A, Schluger NW. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002;346:1453-1458.
7. Sharnprapai S, Miller AC, Suruki R, Corkren E, Etkind S, Driscoll J, McGarry M, Nardell E. Genotyping analyses of tuberculosis cases in US- and foreign-born Massachusetts residents. Emerg Infect Dis 2002;8:1239-1245.
8. US Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Prevention Services, Division of Tuberculosis Control. A strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep 1989;38:269-272.
9. US Department of Health and Human Services, Centers for Disease Control and Prevention. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Recomm Rep 1999;48:1-13.
10. Institute of Medicine. Ending neglect: the elimination of tuberculosis in the United States. Geiter L, editor. Washington DC: National Academy Press; 2000.
11. Ferebee SH, Mount FW, Murray FJ, Livesay VT. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis 1963;88:161-175.
12. Palmer CE, Jablon S, Edwards PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc 1957;76:517-539.
13. Grzybowski S, Allen EA. The challenge of tuberculosis in decline. Am Rev Respir Dis 1964;90:707-720.
14. Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculous infection, and tuberculous disease. Arch Environ Health 1971;22:106-112.
15. Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless. A prospective study. Am J Respir Crit Care Med 2000;162:460-464.
16. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, Friedland GH. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-550. (Pubitemid 19070537)
17. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970;26:28-106.
18. Stead WW, Lofgren JP. Does the risk of tuberculosis increase in old age? J Infect Dis 1983;147:951-955.
19. Sterling TR, Bethel J, Goldberg S, Weinfurter P, Yun L, Horsburgh CR. TBESC. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006;173:927-931.
20. Horsburgh R, O'Donnell M, Chamblee S, Moreland JL, Johnson J, Marsh B, Narita M, Pedrosa M, Johnson LS, von Reyn CF. Population-based assessment of the rate of reactivation tuberculosis in a Southeastern US community [abstract]. Am J Respir Crit Care Med 2009;179:A2200.
21. Stratford D, Chamblee S, Ellerbrock TV, Johnson RJ, Abbott D, Reyn CF, Horsburgh CR. Integration of a participatory research strategy into a rural health survey. J Gen Intern Med 2003;18:586-588.
22. Ellerbrock TV, Chamblee S, Bush TJ, Johnson JW, Marsh BJ, Lowell P, Trenschel RJ, Von Reyn CF, Johnson LS, Horsburgh CR Jr. Human immunodeficiency virus infection in a rural community in the United States. Am J Epidemiol 2004;160:582-588. (Pubitemid 39215635)
23. Reed C, von Reyn CF, Chamblee S, Ellerbrock TV, Johnson JW, Marsh BJ, Johnson LS, Trenschel RJ, Horsburgh CR Jr. Environmental risk factors for infection with Mycobacterium avium complex. Am J Epidemiol 2006;164:32-40. (Pubitemid 43946288)
24. Van Soolingen D. Molecular epidemiology of tuberculosis and other mycobacterial infections: main methodologies and achievements. J Intern Med 2001;249:1-26.
25. Mitchell RM.Mortality and relapse of uncomplicated advanced pulmonary tuberculosis before chemotherapy: 1,504 consecutive admissions followed for fifteen to twenty-five years. Am Rev Tuberc 1955;72:487-501.
26. Alling DW, Bosworth EB. The after-history of pulmonary tuberculosis. VI. The first fifteen years following diagnosis. Am Rev Respir Dis 1960;81:839-849.
27. Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, Weinfurter P; Tuberculosis Epidemiologic Studies Consortium. Latent tuberculosis infection treatment acceptance and completion in 2002 in the United States and Canada. Chest 2010;137:401-409.
28. Comstock GW, Woolpert SF, Livesay VT. Tuberculosis studies in Muscogee County, Georgia. Twenty year evalution of a community trial of BCG vaccination. Public Health Rep 1976;91:276-280.
29. Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. Am J Epidemiol 1974;99:131-138.
30. Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985;312:1483-1487.
31. Stead WW, To T. The significance of the tuberculin skin test in elderly persons. Ann Intern Med 1987;107:837-842.
32. Battershill JH. Cutaneous testing in the elderly patient with tuberculosis. Chest 1980;77:188-189.
33. Palitz LS, Aronsohn MH. Tuberculin sensitivity in the aged. Am Rev Respir Dis 1957;75:461-468.
34. Patel S, Parsyan AE, Gunn J, Barry MA, Reed C, Sharnprapai S, Horsburgh CR Jr. Risk of progression to active tuberculosis among foreign-born persons with latent tuberculosis. Chest 2007;131:1811-1816.
35. Murray M. Sampling bias in the molecular epidemiology of tuberculosis. Emerg Infect Dis 2002;8:363-369. (Pubitemid 34415197)
36. Glynn JR, Bauer J, de Boer AS, Borgdorff MW, Fine PEM, Godfrey-Faussett P, Vynnycky E. Interpreting DNA fingerprint clusters of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 1999;3:1055-1060.
37. McQuillan GM, Ezzati-Rice TM, Siller AB, Visscher W, Hurley P. Risk behavior and correlates of risk for HIV infection in the Dallas County Household HIV survey. Am J Public Health 1994;84:747-753.
38. McQuillan GM, Khare M, Karon JM, Schable CA, Vlahov D. Update on the seroepidemiology of human immunodeficiency virus in the United States household population: NHANES III, 1988-1994. J Acquir Immune Defic Syndr 1997;14:355-360.
39. Horsburgh CR, Chamblee S, Ellerbrock TE, Johnson JW, Marsh B, Johnson LS, von Reyn CF. Dual skin testing to assess misclassification of latent tuberculosis infection among foreign-born persons in the United States (abstract). Proc Am Thorac Soc 2006;3:A505.
40. Rose DN, Schecter CB, Fahs MC, Sulver AL. Tuberculosis prevention: cost-effectiveness of isoniazid chemoprophylaxis. Am J Prev Med 1988;4:102-109.
41. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. Ann Intern Med 1997;127:1051-1061.
42. Taylor Z. The cost-effectiveness of screening for latent tuberculosis infection. Int J Tuberc Lung Dis 2000;4:S127-S133.
43. Rose DN. Benefits of screening for latent Mycobacterium tuberculosis infection. Arch Intern Med 2000;160:1513-1521.